期刊
JOURNAL OF THORACIC ONCOLOGY
卷 11, 期 2, 页码 256-260出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2015.10.010
关键词
Alectinib; ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases
资金
- NCI NIH HHS [C06 CA059267, R01 CA164273, C06CA059267, 5R01CA164273] Funding Source: Medline
The central nervous system (CNS) is an important and increasingly recognized site of treatment failure in anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC) patients receiving ALK inhibitors. In this report, we describe two ALK-positive patients who experienced initial improvements in CNS metastases on standard dose alectinib (600 mg twice daily), but who subsequently experienced recurrences with symptomatic leptomeningeal metastases. Both patients were dose-escalated to alectinib 900 mg twice daily, resulting in repeat clinical and radiographic responses. Our results suggest that dose intensification of alectinib may be necessary to overcome incomplete ALK inhibition in the CNS and prolong the durability of responses in patients with CNS metastases, particularly those with leptomeningeal carcinomatosis. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据